AIM: To determine the presence of systemic inflammation and innate immune responsiveness of patients with a history of acute anterior uveitis but no signs of ocular inflammation at the time of recruitment. METHODS: Tumour necrosis factor alpha (TNF-alpha) production in response to bacterial lipopolysaccharide (LPS) was studied using whole blood culture assay; levels of TNF-alpha in culture supernatants, and soluble interleukin 2 receptor (sIL-2R) in serum were determined by chemiluminescent immunoassay (Immulite); monocyte surface expression of CD11b, CD14, and CD16 and the proportion of monocyte subsets CD14(bright)CD16(-) and CD14(dim)CD16(+) were studied with three colour whole blood flow cytometry; and serum C reactive protein (CRP) levels were determined using immunonephelometric high sensitivity CRP assay. RESULTS: The CRP level (median, interquartile range) was significantly higher in 56 patients with previous uveitis than in 37 controls (1.59 (0.63 to 3.47) microg/ml v 0.81 (0.32 to 2.09) microg/ml; p=0.008). The TNF-alpha concentration of the culture media per 10(5) monocytes was significantly higher in the patient group than in the control group in the presence of LPS 10 ng/ml (1473 (1193 to 2024) pg/ml v 1320 (935 to 1555) pg/ml; p=0.012) and LPS 1000 ng/ml (3280 (2709 to 4418) pg/ml v 2910 (2313 to 3358) pg/ml; p=0.011). The background TNF-alpha release into the culture media was low in both groups. CD14 expression of CD14(bright)CD16(-) monocytes, defined as antibody binding capacity (ABC), was similar for the patients and controls (22,839 (21,038 to 26,020) ABC v 21,657 (19,854 to 25,646) ABC). CONCLUSIONS: Patients with previous acute anterior uveitis show high innate immune responsiveness that may play a part in the development of ocular inflammation.
AIM: To determine the presence of systemic inflammation and innate immune responsiveness of patients with a history of acute anterior uveitis but no signs of ocular inflammation at the time of recruitment. METHODS:Tumour necrosis factor alpha (TNF-alpha) production in response to bacterial lipopolysaccharide (LPS) was studied using whole blood culture assay; levels of TNF-alpha in culture supernatants, and soluble interleukin 2 receptor (sIL-2R) in serum were determined by chemiluminescent immunoassay (Immulite); monocyte surface expression of CD11b, CD14, and CD16 and the proportion of monocyte subsets CD14(bright)CD16(-) and CD14(dim)CD16(+) were studied with three colour whole blood flow cytometry; and serum C reactive protein (CRP) levels were determined using immunonephelometric high sensitivity CRP assay. RESULTS: The CRP level (median, interquartile range) was significantly higher in 56 patients with previous uveitis than in 37 controls (1.59 (0.63 to 3.47) microg/ml v 0.81 (0.32 to 2.09) microg/ml; p=0.008). The TNF-alpha concentration of the culture media per 10(5) monocytes was significantly higher in the patient group than in the control group in the presence of LPS 10 ng/ml (1473 (1193 to 2024) pg/ml v 1320 (935 to 1555) pg/ml; p=0.012) and LPS 1000 ng/ml (3280 (2709 to 4418) pg/ml v 2910 (2313 to 3358) pg/ml; p=0.011). The background TNF-alpha release into the culture media was low in both groups. CD14 expression of CD14(bright)CD16(-) monocytes, defined as antibody binding capacity (ABC), was similar for the patients and controls (22,839 (21,038 to 26,020) ABC v 21,657 (19,854 to 25,646) ABC). CONCLUSIONS:Patients with previous acute anterior uveitis show high innate immune responsiveness that may play a part in the development of ocular inflammation.
Authors: M Roivainen; M Viik-Kajander; T Palosuo; P Toivanen; M Leinonen; P Saikku; L Tenkanen; V Manninen; T Hovi; M Mänttäri Journal: Circulation Date: 2000-01-25 Impact factor: 29.690
Authors: A Takala; I Jousela; S E Jansson; K T Olkkola; O Takkunen; A Orpana; S L Karonen; H Repo Journal: Clin Sci (Lond) Date: 1999-11 Impact factor: 6.124
Authors: S M Opal; P J Scannon; J L Vincent; M White; S F Carroll; J E Palardy; N A Parejo; J P Pribble; J H Lemke Journal: J Infect Dis Date: 1999-11 Impact factor: 5.226
Authors: M Huhtinen; K Laasila; K Granfors; M Puolakkainen; I Seppälä; L Laasonen; H Repo; A Karma; M Leirisalo-Repo Journal: Ann Rheum Dis Date: 2002-11 Impact factor: 19.103
Authors: Cem Ozgonul; Erdim Sertoglu; Onder Ayyildiz; Tarkan Mumcuoglu; Murat Kucukevcilioglu; Gokcen Gokce; Ali Hakan Durukan Journal: Int J Ophthalmol Date: 2017-02-18 Impact factor: 1.779
Authors: Aubrey Hargrave; Justin A Courson; Vanna Pham; Paul Landry; Sri Magadi; Pooja Shankar; Sam Hanlon; Apoorva Das; Rolando E Rumbaut; C Wayne Smith; Alan R Burns Journal: PLoS One Date: 2020-09-04 Impact factor: 3.240
Authors: Maren Kasper; Karoline Walscheid; Björn Laffer; Dirk Bauer; Martin Busch; Lena Wildschütz; Bo Wang; Karin Loser; Thomas Vogl; Rafael S Grajewski; Thomas Langmann; Arnd Heiligenhaus Journal: Front Immunol Date: 2018-07-30 Impact factor: 7.561